| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 95 | — | 17.8x | Top tier | |
Growth | 13 | -21.3% | 7.1% | Bottom tier | |
Quality | 18 | -32.7% | 4.5% | Bottom tier | |
Safety | 32 | — | 2.6x | Bottom tier | |
Capital Return | 36 | 7.19% | 2.12% | Bottom tier | |
Momentum | 16 | -73.4% | 2.9% | Bottom tier | |
Sentiment | 46 | 10 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
FMC Corporation operates in the crop protection market, generating revenue from the sale of branded pesticides and agricultural products and from supplying diamide products to partners. Its portfolio includes Rynaxypyr and Cyazypyr, alongside the new active ingredients Isoflex active, fluindapyr, and Dodhylex active, as well as plant health products. In fiscal year 2025, the company generated revenue of $3.5 billion and gross profit of $1.3 billion, but recorded a net loss of $2.2 billion and a loss per share of $17.88.
Rynaxypyr represents an important part of the commercial mix; its sales reached about $800 million in fiscal year 2025, including $600 million from branded products and $200 million from partner sales. For fiscal year 2026, management expects branded sales to remain near $600 million, while partner sales decline to less than $100 million due to lower prices and volumes following the patent expiration at the end of 2025. By contrast, sales of new active ingredients doubled year over year in Q1 of fiscal year 2026, making Isoflex active, fluindapyr, and Dodhylex active a key focus for growth diversification.
In Q2 of fiscal year 2026, revenue reached $867.1 million and gross profit was $342.1 million, equivalent to a calculated gross margin of about 39.5%, while the net loss was $186.6 million and the loss per share was $1.49. This compares with revenue of $758.6 million, gross profit of $246.6 million, and a net loss of $281.3 million in Q1 of fiscal year 2026, indicating sequential improvement in revenue, margin, and net loss. Nevertheless, the latest twelve-month period of 2026 shows revenue of $3.3 billion, gross profit of $1.1 billion, and a substantial net loss of $2.8 billion.
Automated analysis for informational purposes only — not investment advice.
The average analyst price target is $15, within a wide range of $11 to $21, accompanied by a Neutral consensus; the average target is also about 61% below the 52-week range high of $38.83, reflecting a substantial reassessment relative to the annual peak. The price-to-earnings ratio does not provide a useful anchor given a loss per share of approximately $22.02 and a net loss of $2.8 billion in the latest twelve-month period of 2026, so the valuation rationale is tied more to operational improvement and debt reduction than to stable realized earnings.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
In fiscal year 2025, FMC recorded revenue of $3.5 billion and gross profit of $1.3 billion, but incurred a net loss of $2.2 billion. In the latest twelve-month period of 2026, revenue was $3.3 billion and the net loss was $2.8 billion, with a loss per share of approximately $22.02. Management also expected interest expense of between $255 million and $275 million in fiscal year 2026, alongside about $150 million in cash restructuring spending.
Q2 fiscal year 2026 revenue was approximately $867.1 million, compared with $758.6 million in Q1 of fiscal year 2026. Gross profit increased from $246.6 million to $342.1 million, raising the calculated gross margin from about 32.5% to about 39.5%. The net loss also narrowed from $281.3 million to $186.6 million, and the loss per share declined from $2.25 to $1.49.
The Rynaxypyr patent expired at the end of 2025, so FMC repositioned its pricing to compete with low-cost generic CTPR products. The company expects total Rynaxypyr sales to decline from about $800 million in fiscal year 2025 to approximately $700 million in fiscal year 2026, with branded sales remaining near $600 million and partner sales falling to less than $100 million. Protecting profits depends on reducing costs, increasing volumes, and shifting the mix toward high-concentration formulations and advanced mixtures, which represented about half of Q1 fiscal year 2026 sales.
The new portfolio includes Isoflex active, fluindapyr, and Dodhylex active, and sales of new active ingredients doubled year over year in Q1 of fiscal year 2026. Isoflex active received active ingredient approval in the European Union, and the company aims to launch its products there during 2027 and reach more than 55 million cultivated hectares. fluindapyr has nineteen pending registrations, while about 90% of the target market for Dodhylex is concentrated in Asia, according to management.
The company aims to repay about $1 billion of debt during 2026, compared with net debt of about $4.1 billion as of March 31, 2026. Management said advanced negotiations involving the India business, licensing, non-core molecules, and real estate provided a visible path to about $700 million, or 70% of the target. However, free cash flow for Q1 of fiscal year 2026 was negative $628 million, and fiscal year 2026 guidance ranges from negative $65 million to positive $65 million, so debt reduction depends heavily on completing disposal and licensing transactions.
The analyst consensus on FMC stock is Neutral, with an average price target of $15. The target range extends from $11 to $21, while the stock's 52-week range is between $9.95 and $38.83, and the average target is about 61% below the annual high. With no meaningful price-to-earnings ratio due to losses, the valuation focuses on the company's ability to reduce debt, improve margins, and successfully manage the Rynaxypyr transition following the patent expiration.
